White, Gemma V. published the artcileKallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome, Product Details of C9H10N2O, the publication is Bioorganic & Medicinal Chemistry Letters (2019), 29(6), 821-825, database is CAplus and MEDLINE.
Netherton syndrome (NS) is a rare and debilitating severe autosomal recessive genetic skin disease with high mortality rates particularly in neonates. NS is caused by loss-of-function SPINK5 mutations leading to unregulated kallikrein 5 (KLK5) and kallikrein 7 (KLK7) activity. Furthermore, KLK5 inhibition has been proposed as a potential therapeutic treatment for NS. Identification of potent and selective KLK5 inhibitors would enable further exploration of the disease biol. and could ultimately lead to a treatment for NS. This publication describes how fragmentation of known trypsin-like serine protease (TLSP) inhibitors resulted in the identification of a series of phenolic amidine-based KLK5 inhibitors 1. X-ray crystallog. was used to find alternatives to the phenol interaction leading to identification of carbonyl analogs such as lactam 13 and benzimidazole 15. These reversible inhibitors, with selectivity over KLK1 (10-100 fold), provided novel starting points for the guided growth towards suitable tool mols. for the exploration of KLK5 biol.
Bioorganic & Medicinal Chemistry Letters published new progress about 7467-35-8. 7467-35-8 belongs to imidazoles-derivatives, auxiliary class Benzimidazole,Alcohol, name is (1-Methyl-1H-benzo[d]imidazol-2-yl)methanol, and the molecular formula is C7H11N3O2, Product Details of C9H10N2O.
Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem